Developments Nabriva XENLETA gets European approval for community-acquired pneumonia The EMA approved Nabriva Therapeutics’ (NASDAQ:NBRV) XENLETA for the treatment of community-acquired pneumonia. The approval is based on efficacy data from two Phase 3 clinical trials, both of which established XENLETA... July 28, 2020